T. Rowe Price Associates
CSTL icon

T. Rowe Price Associates’s Castle Biosciences CSTL Stock Holding History

T. Rowe Price Associates’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
53,242
+15,450
+41% +$344K ﹤0.01% 2212
2026
Q1 		$928K Buy
37,792
+3,654
+11% +$120K ﹤0.01% 2198
2025
Q4 		$1.33M Buy
34,138
+1,545
+5% +$49.8K ﹤0.01% 1960
2025
Q3 		$743K Buy
32,593
+6,186
+23% +$126K ﹤0.01% 2195
2025
Q2 		$540K Buy
26,407
+2,702
+11% +$50K ﹤0.01% 2266
2025
Q1 		$475K Buy
23,705
+1,008
+4% +$25K ﹤0.01% 2266
2024
Q4 		$605K Buy
22,697
+1,837
+9% +$55.9K ﹤0.01% 2203
2024
Q3 		$595K Buy
20,860
+212
+1% +$5.4K ﹤0.01% 2184
2024
Q2 		$450K Buy
20,648
+2,614
+14% +$58.3K ﹤0.01% 2226
2024
Q1 		$400K Buy
18,034
+1,131
+7% +$24.6K ﹤0.01% 2295
2023
Q4 		$365K Buy
16,903
+428
+3% +$7.53K ﹤0.01% 2312
2023
Q3 		$279K Buy
16,475
+1,009
+7% +$17.6K ﹤0.01% 2360
2023
Q2 		$213K Buy
15,466
+182
+1% +$3.69K ﹤0.01% 2506
2023
Q1 		$348K Buy
15,284
+303
+2% +$7.4K ﹤0.01% 2272
2022
Q4 		$353K Sell
14,981
-1,615
-10% -$37.4K ﹤0.01% 2311
2022
Q3 		$433K Buy
16,596
+2,957
+22% +$82.9K ﹤0.01% 2194
2022
Q2 		$299K Sell
13,639
-28
-0.2% -$651 ﹤0.01% 2440
2022
Q1 		$613K Buy
13,667
+3,723
+37% +$154K ﹤0.01% 2248
2021
Q4 		$426K Buy
9,944
+3,209
+48% +$168K ﹤0.01% 2463
2021
Q3 		$448K Buy
6,735
+1,363
+25% +$95.9K ﹤0.01% 2427
2021
Q2 		$394K Buy
5,372
+792
+17% +$52.3K ﹤0.01% 2484
2021
Q1 		$314K Buy
4,580
+679
+17% +$51K ﹤0.01% 2552
2020
Q4 		$262K Buy
+3,901
New +$211K ﹤0.01% 2470

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's CSTL Position: Q2 2026 in Review

T. Rowe Price Associates increased its Castle Biosciences (CSTL) stake by 41% in Q2 2026, buying an estimated $344K and bringing the position to 53,242 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

T. Rowe Price Associates first reported a position in CSTL in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.33M in Q4 2025. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • T. Rowe Price Associates held 53,242 shares of Castle Biosciences worth $1.27M as of Q2 2026.
  • T. Rowe Price Associates bought 15,450 Castle Biosciences shares in Q2 2026, an estimated $344K.
  • Castle Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2212 holding.
  • T. Rowe Price Associates first reported a position in Castle Biosciences in Q4 2020 and has held it in 23 quarters since.
  • T. Rowe Price Associates's Castle Biosciences position peaked at $1.33M in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.